TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02446652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine/Magnesium
Description: (Hydralazine: 1 oral tablet every 24 hours, 182 mg for rapid acetylators, and 83 mg for low acetylators and Magnesium valproate: orally 30 mg/K weight every 8 hours) starting 1 week prior the first day of the QT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (orally) starting 1 week before the first day of the QT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 5 AUC 1 hour/day 1 for every 21 days for 6 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: 5 AUC 1 hour/day 1 for every 21 days for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175mg/m2/SC 3hour/day 1 for every 21 days for 6 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175mg/m2/SC 3hour/day 1 for every 21 days for 6 cycles.
Study: NCT00872898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine - Extended Release (ER)
Description: Memantine - 3mg and 6mg capsules, dose ranging 3 - 18 mg/day in 4 weight groups, administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, once daily, oral administration.
Study: NCT03065803

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal plate expansion technique for dental socket preservation
Description: An internal osteotomy of the socket buccal plate will be performed with a piezotome (SurgyStar).~Two vertical osteotomies and one horizontal osteotomy will be made to push the buccal plate outward from the socket. Two small cervical releasing incisions will be made in the mesiobuccal and distobuccal aspects of the socket to permit the displacement of the osteotomies in the area of keratinized tissue. The socket will be loaded with natural bovine bone mineral (cerabone). The biomaterial will be pressed to push the released buccal plate outward. A collagen bio absorbable membrane will be utilized to cover the socket. The collagen membrane plug will be stabilized on the top of the socket with a cross suture (silk 4/0).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Guided bone regeneration technique for post-extraction dental socket preservation
Description: After full-thickness flap reflection on buccal and lingual sides, atraumatic tooth extraction utilizing periotome will be performed.The periosteum of buccal flap will be incised; this would permit coronal advancement of facial flap and a tension-free primary closure. Extraction sockets will be grafted with natural bovine bone mineral (cerabone). Collagen membrane will be trimmed and placed on the grafted socket and alveolar bone.. Buccal and lingual/palatal flaps will be approximated utilizing interrupted simple loop and vertical mattress sutures (4/0)
Study: NCT04570449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: 20 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: fluoxetine placebo capsule
Study: NCT01422304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex 4 mg/kg intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neostigmine and glycopyrrolate or atropine
Description: Neostigmine and glycopyrrolate or neostigmine and atropine administered intravenously per usual practice and per the product labels
Study: NCT02390999

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 48 hours of therapeutic hypothermia
Study: NCT00951873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII, long acting
Description: Single injection of long acting activated recombinant human factor VII subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single injection of long acting activated recombinant human factor VII placebo subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII, long acting
Description: Single dose of 0,1 mg/kg long acting activated recombinant human factor VII injected intravenously (into a vein).
Study: NCT01270555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Description: 100mg capsules Initial dosing 100mgSR every morning, to be titrated to 200mgSR twice daily maximum
Study: NCT02289014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online stress Management program
Description: Active treatment group
Study: NCT00610584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetirizine dihydrochloride (rescue medication)
Description: arm 3: rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily)) alone
Study: NCT00907062

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba
Description: 60 mg Ginkgo biloba per capsule, standardized to 15 mg ginkgofavonglycosides per pill
Study: NCT03785743

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TLPD Surgery
Description: TLPD

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OPD Surgery
Description: OPD
Study: NCT01692873

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suspected pancreatic tumor
Description: Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.
Study: NCT03949491

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D medical models
Description: Using 3D medical models of the abdomen, a virtual plan will assist reconstruction to clearly define and 3D model the normal and aberrant vascular anatomy of the donor site in order to decrease both operative time and dissection time. This will also allow for the proposal of incision lines to match the corresponding volumetric analysis of the transposed tissue in order to facilitate the creation of a patient specific tailored flap, which will improve the aesthetic outcomes, decrease donor site complications and improve patient satisfaction
Study: NCT03832244

Intervention type: DIAGNOSTIC_TEST
Intervention: Sub-mental ultrasonography
Description: Sub-mental ultrasonography including tongue-base thickness, retropalatal distance and the distance between lingual arteries

Intervention type: DIAGNOSTIC_TEST
Intervention: Sub-mental ultrasonography
Description: Sub-mental ultrasonography including tongue-base thickness, retropalatal distance and the distance between lingual arteries

Intervention type: DIAGNOSTIC_TEST
Intervention: Sub-mental ultrasonography
Description: Sub-mental ultrasonography including tongue-base thickness, retropalatal distance and the distance between lingual arteries

Intervention type: DIAGNOSTIC_TEST
Intervention: Sub-mental ultrasonography
Description: Sub-mental ultrasonography including tongue-base thickness, retropalatal distance and the distance between lingual arteries
Study: NCT00312403

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Sample
Description: A single venous blood sample will be taken (10 ml).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Sample
Description: A single venous blood sample will be taken (10 ml).
Study: NCT03204786

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vasopressin (USP) Injectable Solution [Vasostrict]
Description: Nasal Spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin (USP) Injectable Solution [Vasostrict]
Description: Nasal Spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin (USP) Injectable Solution [Vasostrict]
Description: Nasal Spray
Study: NCT01592240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBO
Description: Placebo, Q14d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04950615
Description: PF-04950615 50mg, Q14d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04950615
Description: PF-04950615 100 mg, Q14d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04950615
Description: PF-04950615 150mg, Q14d
Study: NCT01298050

Intervention type: PROCEDURE
Intervention: ECMO
Description: Insertion of peripheral Veno-Arterious ECMO, subsequent therapeutic hypothermia
Study: NCT02751437

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine
Study: NCT01189747

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: 24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Injected into bilateral Crow's Feet Line areas on Day 1
Study: NCT03234127

Intervention type: GENETIC
Group type: OTHER
Intervention: Whole Genome Sequencing
Description: Whole Genome Sequencing Biomarkers analyses

Intervention type: GENETIC
Group type: OTHER
Intervention: Whole Genome Sequencing
Description: Whole Genome Sequencing Biomarkers analyses

Intervention type: GENETIC
Group type: OTHER
Intervention: Whole Genome Sequencing
Description: Whole Genome Sequencing Biomarkers analyses
Study: NCT00649974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valtrex® Tablets 1000 mg
Description: 1000mg, single dose fasting
Study: NCT01422304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to neostigmine
Description: Normal saline (NaCl 0.9%)
Study: NCT04495543

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Skills for Safer Living
Description: Brief-SfSL is a single-session individual therapy adaptation of the core goals/principles of the 20-week SfSL group therapy. Brief-SfSL incorporates the SfSL guiding principles of emphasizing safety, attending to the therapeutic relationship, recognizing the participant as the expert in their own experience, taking a trauma-informed approach, working with emotions while recognizing the role of alexithymia, and incorporating solution-focused concepts. The goal is to increase a person's understanding and capacity to engage in what would enable them to keep safe, even if thoughts of suicide are present. The intervention procedure is dynamic, but includes 4 core tasks: 1) understanding the individual's suicidal experience, 2) skills building, 3) developing a safety plan, and 4) identifying obstacles to enacting or engaging with the safety plan.
Study: NCT03983135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laparoscopic mini gastric by-pass
Description: Adhesions will separated along the left edge of the stomach and the left lobe of the liver. The remnant stomach will transected at the incisura angularis level with 60 mm Endo-GIA stapler(ATW 35, EthiconEndo-SurgeryInc., Cincinnati, OH, USA). Later ante-cholic distal of the Treitz ligament hadgastro-jejunal anastomosisof nearly 150 cm jejunal loop performed with 44 mm Endo-GIA stapler. Routinely, the omentum will be divided in two and omentopexy will be performed around the anastomosis. The stapler line will supported by absorbable stitches.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LaparoscopicRe-sleeve gastrectomy
Description: Adhesions will be separated with blunt and sharp dissections, then the remnant stomach will completely freed. Due to dilated antral pouch or fundus, the remnant stomach will resect as a tube stomach between the pillory and left crus with 60 mm Endo-GIA stapler accompanied by 36F bougie.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Ygastric bypass
Description: all adhesions will separated then after the stomach pouch will formed by the linear stapler, 100 cm of jejunum will transected from the Treitz ligament. Side-to-side gastrojejunostomy will performed for the distal jejunum with the linear stapler. The anterior face of the anastomosis will manually sutured. Proximal jejunum end hadside-to-side jejuno-jejunostomy performed 150 cm distal of the gastrojejunostomy anastomosis with linear stapler on the posterior wall and manual suturing of the anterior wall.
Study: NCT00963495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clioquinol
Description: Patients will take Clioquniol at escalating doses depending on when they enter into the trial.
Study: NCT01422304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to sugammadex
Description: Normal saline (NaCl 0.9%)
Study: NCT04772157

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Troponin Testing
Description: Lithium heparin whole blood and plasma samples will be measured with Siemens POC High Sensitivity Troponin-I Test System.
Study: NCT04467840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opaganib
Description: Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, or matching placebo, in addition to standard of care (pharmacological as defined above and/or supportive) at any given institution. Study drug will be administered every day for 14 days (Day 1 to Day 14).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, or matching placebo, in addition to standard of care (pharmacological as defined above and/or supportive) at any given institution. Study drug will be administered every day for 14 days (Day 1 to Day 14).
Study: NCT02369315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment (Invited entry 2012)
Description: Entry to music program offered in September 2012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control (Invited entry 2013)
Description: Entry to music program offered in September 2013
Study: NCT04436003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle and articulation chains GDS method
Description: A physiotherapy method adapting treatment to patient's terrain, or psychomorphology, using chosen techniques to balance tension between muscle chains, thus optimalizing posture and mouvement.
Study: NCT04439487

Intervention type: DIAGNOSTIC_TEST
Intervention: Anthropometric measurements during routine preoperative visit
Description: During routine preoperative anaesthetic visit and physical examination the following predictive test measurements are obtained by a research team member not involved in the further assessment of laryngoscopy: score in modified Mallampati test, Thyromental height, Sternomental distance, Thyromental distance, Neck circumference, Mouth opening distance

Intervention type: OTHER
Intervention: Assesment of intubation parameters during induction of general anaesthesia
Description: During induction of general anaesthesia and intubation research team member not involved in obtaining anthropometric measurements notes Number of intubation attempts, Intubation time, Subjective intubation difficulty, Use of bougie and Need of technique modification.
Study: NCT03044093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: The group that will get in addition to Misoprostol also Mifepristone
Study: NCT02042560

Intervention type: OTHER
Intervention: Blood samples

Intervention type: OTHER
Intervention: Blood samples

Intervention type: OTHER
Intervention: Spleen samples
Study: NCT00114504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: simvastatin 5-10 mg/day
Study: NCT01187823

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive servo ventilation
Description: Nocturnal use of Adaptive servo ventilation
Study: NCT03044093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The group that will only get Misoprostol
Study: NCT01187823

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nocturnal oxygen
Description: Nocturnal use of oxygen
Study: NCT03921762

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery with Artis Active IOLs
Description: Patients will be implanted with the Artis Active IOLs during cataract surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery with AT Lara IOLs
Description: Patients will be implanted with the AT Lara IOLs during cataract surgery
Study: NCT01847235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle).
Study: NCT03044093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Both groups will get think drug
Study: NCT00937664

Intervention type: DRUG
Group type: OTHER
Intervention: AZD7762
Description: solution, intravenous, weekly
Study: NCT03044093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Both groups will get think drug
Study: NCT03113162

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEAM Regimen
Description: Reduced-intensity BEAM for Immunoablation
Study: NCT03148080

Intervention type: PROCEDURE
Intervention: Cognitive Assessment
Description: Complete CogState
Study: NCT00937664

Intervention type: DRUG
Group type: OTHER
Intervention: gemcitabine
Description: intravenous, weekly
Study: NCT03596710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image Guided Biopsy
Description: Undergo image guided biopsy
Study: NCT03397719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Condition
Description: This group will receive three hours of parent coaching per week, one hour per week will involve feedback on parent usage of coached strategies based on parent recorded interactions with their children.
Study: NCT03148080

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete Self-Report Questionnaire
Study: NCT01608438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customizing the Body-Machine Interface
Description: The intervention compares two ways of customizing the body-machine interface which will be used for subjects for 40 sessions (spread over 8 months). In one case (SCI static), the body-machine interface is static. In the other case (SCI Machine Learning), there is a machine learning algorithm that adapts to the movements made by the subject.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customizing the Body-Machine Interface
Description: The intervention compares two ways of customizing the body-machine interface which will be used for subjects for 40 sessions (spread over 8 months). In one case (SCI static), the body-machine interface is static. In the other case (SCI Machine Learning), there is a machine learning algorithm that adapts to the movements made by the subject.
Study: NCT02716597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25% Albumin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02985333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 170 mg/m(2) IV over 3 h d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 200mgmg/m(2) IV d1,3,5
Study: NCT03112031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen will be given orally in a dose of 300mg/day for the first 14 days following randomization. It will be administered by nasogastric tube where patients are unconscious. The Tamoxifen will be administered in the morning combined with amphotericin and fluconazole dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphotericin B
Description: Patients will receive amphotericin 1mg/kg/day i.v. once daily orally for the first 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Description: Patients will receive amphotericin 1mg/kg/day i.v. once daily orally for the first 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Patients will receive fluconazole 800mg once daily orally for the first 2 weeks. Amphotericin and fluconazole will be administered simultaneously. After the first 2 weeks of study treatment, all patients will receive fluconazole 800mg/day for 8 further weeks, until the study end.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Patients will receive fluconazole 800mg once daily orally for the first 2 weeks. Amphotericin and fluconazole will be administered simultaneously. After the first 2 weeks of study treatment, all patients will receive fluconazole 800mg/day for 8 further weeks, until the study end.
Study: NCT00591760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatotropin
Description: Subcutaneous Somatotropin (recombinant human Growth Hormone) 0.012 mg/kg every second day for 6 months
Study: NCT02985333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20mg iv d1-4
Study: NCT03397719

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: This group will receive in-vivo parent coaching three hours per week.
Study: NCT02161705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg) administered in paravertebral block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Up to 0.8 mL/kg of normal saline administered
Study: NCT00089583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEXIVA (GW433908)
Description: Fosamprenavir suspension or tablet bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEXIVA (GW433908)
Description: Fosamprenavir suspension or tablet bid
Study: NCT02886728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily
Study: NCT01131260

Intervention type: DEVICE
Group type: OTHER
Intervention: fetal STAN monitor
Description: The STAN monitor is a system for fetal surveillance that displays the FHR, the uterine activity and information resulting from the analysis of the ST segment of the fetal ECG.
Study: NCT02886728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily
Study: NCT01131260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fetal STAN monitor
Description: The STAN monitor is a system for fetal surveillance that displays the FHR, the uterine activity and information resulting from the analysis of the ST segment of the fetal ECG.